David C Rowley

Title: David C Rowley: Innovator in Enzyme Inhibition

Introduction

David C Rowley is a notable inventor based in Encinitas, CA (US). He has made significant contributions to the field of enzyme inhibitors, particularly in the development of therapeutic agents for diseases characterized by abnormal thrombosis. With a total of 2 patents, Rowley's work has the potential to impact medical treatments significantly.

Latest Patents

Rowley's latest patents include innovative compounds that serve as enzyme inhibitors. The first patent, titled "3-amino-2-oxo-1-piperidnercetic derivatives as enzyme inhibitors," discloses peptide aldehydes that are potent and specific inhibitors of thrombin. This invention also covers their pharmaceutically acceptable salts, compositions, and methods of use as therapeutic agents. The second patent, "3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors," presents similar findings, emphasizing the importance of these compounds in treating abnormal thrombosis in mammals.

Career Highlights

David C Rowley is associated with Corvas International, Inc., where he continues to innovate in the field of enzyme inhibition. His work is characterized by a commitment to developing effective therapeutic solutions for complex medical conditions.

Collaborations

Rowley has collaborated with notable professionals in his field, including Joseph Edward Semple and Robert J Ardecky. These collaborations have likely contributed to the advancement of his research and the successful development of his patents.

Conclusion

David C Rowley's contributions to enzyme inhibition represent a significant advancement in therapeutic research. His innovative patents and collaborations highlight his dedication to improving medical treatments for diseases related to abnormal thrombosis.